Variants at 6q21 implicate PRDM1 in the etiology of therapy-induced second malignancies after Hodgkin's lymphoma

Nature Medicine

Volumn 17, Issue 8, 2011, Pages 941-943

  Best, Timothy ^a   Li, Dalin ^b   Skol, Andrew D ^a   Kirchhoff, Tomas ^c   Jackson, Sarah A ^a   Yasui, Yutaka ^d   Bhatia, Smita ^e   Strong, Louise C ^f   Domchek, Susan M ^g   Nathanson, Katherine L ^g   Olopade, Olufunmilayo I ^a   Huang, R Stephanie ^a   MacK, Thomas M ^b   Conti, David V ^b   Offit, Kenneth ^c   Cozen, Wendy ^b   Robison, Leslie L ^h   Onel, Kenan ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^d UNIVERSITY OF ALBERTA   (Canada)

^e Department of Population Sciences ^*  (United States)

^f UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^g UNIVERSITY OF PENNSYLVANIA   (United States)

^h ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B LYMPHOCYTE INDUCED MATURATION PROTEIN 1;

ADOLESCENT; ADULT; ARTICLE; CANCER SURVIVOR; CHILD; CHROMOSOME 6Q; CHROMOSOME VARIANT; CONTROLLED STUDY; GENE EXPRESSION; GENE INTERACTION; GENE LOCUS; GENETIC ASSOCIATION; HODGKIN DISEASE; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN FUNCTION; RADIATION EXPOSURE; RADIATION INDUCED NEOPLASM; SCHOOL CHILD;

AGE FACTORS; CHROMOSOMES, HUMAN, PAIR 6; DOSE-RESPONSE RELATIONSHIP, RADIATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENOTYPE; HAPLOTYPES; HODGKIN DISEASE; HUMANS; MUTATION; NEOPLASMS, SECOND PRIMARY; POLYMORPHISM, SINGLE NUCLEOTIDE; PRINCIPAL COMPONENT ANALYSIS; PROTO-ONCOGENE PROTEINS C-MYC; RADIOTHERAPY; REPRESSOR PROTEINS;

EID: 79961155567     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm.2407     Document Type: Article

References (20)

1. Friedman, D.L. et al. J. Natl. Cancer Inst. 102, 1083-1095 (2010).
2. Meadows, A.T. et al. J. Clin. Oncol. 27, 2356-2362 (2009).
3. Travis, L.B. et al. J. Am. Med. Assoc. 290, 465-475 (2003).
4. Constine, L.S. et al. Int. J. Radiat. Oncol. Biol. Phys. 72, 24-33 (2008).
5. Neglia, J.P. et al. J. Natl. Cancer Inst. 93, 618-629 (2001).
6. Thomas, D. Nat. Rev. Genet. 11, 259-272 (2010).
7. Robison, L.L. et al. Cancer 104, 2557-2564 (2005).
8. Devlin, B. & Roeder, K. Biometrics 55, 997-1004 (1999).
9. Price, A.L. et al. Nat. Genet. 38, 904-909 (2006).
10. Durbin, R.M. et al. Nature 467, 1061-1073 (2010).
11. Nicolae, D.L. et al. PLoS Genet. 6, e1000888 (2010).
12. Calame, K. J. Immunol. 185, 3-4 (2010).
13. Calado, D.P. et al. Cancer Cell 18, 580-589 (2010).
14. Mandelbaum, J. et al. Cancer Cell 18, 568-579 (2010).
15. Beroukhim, R. et al. Nature 463, 899-905 (2010).
16. Behrens, C. et al. Cancer Epidemiol. Biomarkers Prev. 9, 1027-1035 (2000).
17. Lin, Y., Wong, K. & Calame, K. Science 276, 596-599 (1997).
18. Raychaudhuri, S. et al. Nat. Genet. 41, 1313-1318 (2009).
19. Gateva, V. et al. Nat. Genet. 41, 1228-1233 (2009).
20. O'Brien, M.M., Donaldson, S.S., Balise, R.R., Whittemore, A.S. & Link, M.P. J. Clin. Oncol. 28, 1232-1239 (2010).